AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Ado

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr

Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperf

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?

Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

Altimmune NASDAQ: ALT management used an appearance at the Goldman Sachs Global Healthcare Conferenc

Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 da

Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set

Altimmune NASDAQ: ALT executives said the company is preparing to begin enrolling patients in the se

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or d

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data

“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-s

The data are being presented today and Friday in poster sessions, including a late-breaking poster p

Concurrent improvement across key non-invasive tests underscores convergence of  pemvidutide effects

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA

ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy a

ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash run

Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and

Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript

Altimmune NASDAQ: ALT said it has strengthened its balance sheet and is preparing to begin a global

Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in "

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.18) per share which beat the analyst consens

Altimmune shares fall after a $225 million offering raises dilution concerns while funding key late-

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 t

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy a

B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.27) per share. This is a 18.18 percent incre

Altimmune shares are tumbling on Wednesday following the company's announcement of a $75 million

Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy

ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designatio

Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing therapies t